Ruxolitinib

(Jakafi)

Ruxolitinib

Drug updated on 11/16/2023

Dosage FormTablet (oral; 5 mg, 10 mg, 15 mg, 20 mg, 25 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.
  • For treatment of polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.
  • For treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.
  • For treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Product Monograph / Prescribing Information

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.2023Frontiers in Immunology
Single Technology Appraisal Ruxolitinib for treating polycythaemia vera (review of TA356) [ID5106] Committee Papers.2023NICE
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.2023Cancer
Assessment report: Jakavi.2022EMA
Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: systematic review and meta-analysis of randomised and non-randomised studies.2022PLOS ONE
Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.2022Frontiers in Immunology
Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.2022Transplant Immunology
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.2021ICER
Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis.2021Hematology
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.2021Blood Cancer Journal
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.2020Blood Advances
Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis.2020Expert Review of Hematology
Ruxolitinib in the treatment of polycythemia vera: an update on health-related quality of life and patient-reported outcomes.2019Journal of Blood Medicine
Ruxolitinib-associated infections: a systematic review and meta-analysis.2018American Journal of Hematology
Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.2018Current Medical Research and Opinion

Clinical Practice Guidelines